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ABSTRACT
Interferon-a (IFNa) may exert direct inhibitory effects on cell pro-
liferation and on the production of different peptide hormones. We
investigated the effect of IFNa on hormone production by 15 GH-
secreting pituitary adenomas, 4 clinically nonfunctioning or gonado-
troph pituitary adenomas, and 4 prolactinomas in vitro. In the GH-
secreting pituitary adenoma cultures, a short term (72-h) incubation
with IFNa (50–100 U/mL) significantly inhibited GH secretion in 3
of 7 cases and PRL secretion in 6 of 7 cultures. During prolonged
incubation (14 days) with IFNa, GH and/or PRL secretion was sig-
nificantly inhibited in 7 of 8 cultures (GH, 17–78% inhibition; PRL,
39–88% inhibition). In the clinically nonfunctioning or gonadotroph
cultures, incubation with IFNa resulted in inhibition of the secretion
of gonadotropins and/or a-subunit in all cases (27–62%), whereas in
the prolactinoma cultures PRL secretion was inhibited by IFNa in all
cases (37–76%). The effect of IFNa was additive to the inhibitory
effects of the dopamine agonist bromocriptine (10 nmol/L) or the
somatostatin analog octreotide (10 nmol/L). The inhibition of hormone
secretion by IFNa was accompanied by inhibition of the intracellular
hormone concentrations. The effect of IFNa was dose dependent, with
an IC50 for inhibition of hormone secretion of 2.3 6 0.3 U/mL (n 5 5),
which is relatively low compared with the concentrations that are
reached in patients treated with IFNa for various malignancies. In
conclusion, the potent antihormonal effect of IFNa on cultured pitu-
itary adenomas suggests that this drug might be of benefit in the
treatment of selected patients with secreting pituitary adenomas. As
treatment with IFNa is associated with considerable adverse reac-
tions, studies with this drug should only be considered in inoperable,
invasive aggressive, and dopamine agonist- and/or somatostatin an-
alog-resistant functioning pituitary macroadenomas. (J Clin Endo-
crinol Metab 84: 3336–3343, 1999)
INTERFERONS (IFNs) are glycoproteins produced in re-sponse to viral and certain nonviral stimuli. Apart from
having antiviral activity, IFNs are potent inhibitors of cell
proliferation as well. Because of these properties IFNs have
been approved for clinical use to treat certain viral diseases,
autoimmune diseases, and malignancies (1). During the past
10 yr evidence has emerged that IFNs may play a regulatory
role in pituitary hormone secretion as well. Both stimulatory
and inhibitory effects of IFNs (IFNa and IFNg) on the se-
cretion of ACTH, PRL, and GH have been reported (2–6).
Apart from cells of the immune system, pituitary endocrine
cells may also contain IFNa (7), providing further evidence
for a local regulatory role for this group of proteins at the
pituitary level. Moreover, Katahira et al. (8) recently showed
that prolonged incubation with IFNa or IFNg induces a
potent inhibitory effect on POMC gene expression in mouse
AtT-20 pituitary tumor cells.
Until now, IFNa has been used with variable success in the
treatment of hormone-secreting gastroenteropancreatic tu-
mors (mainly carcinoids). Treatment with IFNa may control
tumor growth, but also reduces the secretion of tumor-re-
lated products in patients harboring these tumors, thereby
improving clinical symptomatology (9–11). The decrease in
the production of different peptide hormones is caused by its
blocking effect on intracellular messenger ribonucleic acid
formation (12) and appears to be signalled via the JAK (Janus
kinase)-STAT (signal transducer and activator of transcrip-
tion) pathway (13).
Medical therapy of human pituitary adenomas comprises
the use of dopamine (DA) agonists and somatostatin (SS)
analogs. In patients with prolactinomas, treatment with DA
agonists effectively reduces circulating PRL levels and tumor
size in the majority of them, probably due to an inhibitory
effect on PRL synthesis. However, a small subgroup of pa-
tients with prolactinomas is either resistant to DA agonist
therapy or cannot be treated due to intolerance to therapy
with DA agonists (14). In patients with acromegaly, good
inhibition of circulating GH levels has been achieved using
SS analogs such as octreotide, whereas tumor shrinkage is
observed less frequently (15). This is probably due to the
absence of an inhibitory effect of SS analogs on GH synthesis
(16, 17). Finally, the effectiveness of the use of DA agonists
and/or SS analogs in the medical treatment of clinically
nonfunctioning pituitary adenomas (NFA) is still under dis-
cussion (18).
The presence of IFNa in pituitary endocrine cells, its mod-
ulating effect on pituitary hormone secretion (and/or pro-
duction), and the observations that IFNs act at the transcrip-
tional level suggest that IFNs may also influence hormone
secretion by pituitary adenomas. To further explore the pos-
sibilities of medical therapy of pituitary adenomas, we in-
vestigated in the present study the effect of IFNa-2a on
hormone secretion by different types of cultured human
pituitary adenoma cells. In addition, the interrelationship
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between the effects of IFNa and octreotide and/or bro-
mocriptine was studied. Moreover, a comparison was made
with the effects of IFNa on hormone secretion by primary
cultures of three insulinomas and one gastrinoma.
Subjects and Methods
Patients
Pituitary tumor samples were obtained by transsphenoidal operation
from 15 patients with GH-secreting pituitary adenomas, from 4 patients
with clinically nonfunctioning (n 5 2) or gonadotroph (n 5 2) adenomas,
and from 4 patients with prolactinomas, as described previously (19).
Tumor samples of 3 insulinomas and 1 gastrinoma were obtained within
30 min after surgical removal of the tumors. Diagnosis was made on the
basis of clinical and biochemical characteristics of the patients in com-
bination with (immuno)histochemistry of the tumor samples. The two
patients with gonadotroph adenomas had elevated preoperative levels
of FSH. All patients gave their informed consent for the use of tumor
material for research purposes.
Cell dispersion and cell culture
Single cell suspensions of the pituitary adenoma tissues were pre-
pared by enzymatic dissociation with dispase as described in detail
previously (19). Tumor tissue from the insulinomas and the gastrinoma
was dissociated as described (20). For short term incubation of mono-
layer cultures, the dissociated cells were plated in 48-well plates (Costar,
Cambridge, MA) at a density of 105 (GH-secreting pituitary adenomas,
prolactinomas, insulinomas, and gastrinoma) or 2 3 105 (NFAs) cells/
wellz1 mL culture medium. After 3–4 days the medium was changed,
and 72-h incubations without or with test substances were initiated. At
the end of the incubation the medium was removed and centrifuged for
5 min at 600 3 g. The supernatant was collected and stored at 220 C until
analysis. For long term incubation studies in Transwells (21), the isolated
tumor cells were plated in Transwell-COL membranes (Costar, Badho-
evedorp, The Netherlands) at a density of 105 (GH-secreting pituitary
adenomas, prolactinomas, insulinomas, and gastrinoma) or 2 3 105
(NFAs) cells/well. The Transwells were then placed into multiwell
plates (24-well; Costar) containing 1 mL culture medium. After 72 h the
Transwells were transferred to wells containing fresh medium (without
or with test substances). Every 3–4 days the cells were placed into fresh
medium, and the incubation media were collected and stored at 220 C
until determination of hormone concentrations. In some experiments,
intracellular hormone concentrations were determined in cell lysates
obtained by lysis of the cells in 150 mL ammonia solution (0.2%, vol/vol),
followed by the addition of 1 mL assay buffer (100 mmol/L NaCl, 10
mmol/L ethylenediamine tetraacetate, and 10 mmol/L Tris-HCl, pH
7.0), as described previously (22). In the NFA cultures cell lysates were
obtained by lysis of the cells in distilled water containing 1 g/L BSA
followed by repeated freezing and thawing, as described previously
(21).
The cells were cultured at 37 C in a CO2 incubator. The culture
medium consisted of MEM d-valine with Earle’s salts supplemented
with non essential amino acids, sodium pyruvate (1 mmol/L), 10% FCS,
penicillin (1 3 105 U/L), fungizone (0.5 mg/L), l-glutamine (2 mmol/L),
and sodium bicarbonate (2.2 g/L), pH 7.6. Unfortunately, generally not
FIG. 1. The effect of IFNa (50–100 U/mL) on GH and/or PRL secretion by 15 cultured human GH-secreting pituitary adenomas. Incubation
time was 3 days in multiwell plates (left panel) or 14 days in Transwell tissue culture inserts (right panel). Values are expressed as the percentage
of control hormone release and represent the mean 6 SE. *, P , 0.05 vs. control. ND, Not detectable. M, Control; f, IFNa.
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enough tumor material was obtained to test each tumor for its respon-
siveness to all of the above indicated drugs.
Hormone determinations
Human GH, PRL, LH, and FSH concentrations in the media and cell
extracts were determined by immunoradiometric assays (MedGenix
Diagnostics, Fleurus, Belgium) as described previously (19, 21). Glyco-
protein a-subunit concentrations were determined using an immuno-
radiometric assay from Immunotech S.A. (Marseille, France). Insulin
and gastrin concentrations were determined by double antibody RIAs
as previously described (20). Dilution of GH, PRL, LH, FSH, a-subunit,
insulin, and gastrin in the media was parallel to that of the respective
standards supplied with kits.
Testsubstances
Octreotide (Sandostatin) and bromocriptine were obtained from No-
vartis Pharma A.G. (Basel, Switzerland). IFNa-2a (Roferon-A) was ob-
tained from Hoffmann-La Roche B.V. (Mijdrecht, The Netherlands).
Measurement of DNA content
The DNA content in the cell lysates (see above) was measured using
the bisbenzimide fluorescent dye (Behring, La Jolla, CA) as described in
detail previously (22).
Statistical analysis of the data
All data for hormone release are expressed as the mean 6 se (n 5 4
wells/treatment group). All data were analyzed by ANOVA to deter-
mine overall differences between treatment groups. When significant
differences were found by ANOVA, a comparison between treatment
groups was made using the Newman-Keuls test.
Results
Pituitary adenomas
First, tumor cell preparations from 15 acromegalics were
studied. IFNa (50–100 U/mL) significantly inhibits GH se-
cretion in 3 of 7 cultures (16–69% inhibition) and PRL se-
cretion in 6 of 7 cultures (21–56% inhibition) during a 72-h
incubation (Fig. 1, left panel). A significantly higher number
of cultures responded to IFNa after prolonged exposure.
After 14 days of treatment, GH secretion was significantly
inhibited in 7 of 8 other tumor cell cultures (17–78% inhibi-
tion), and PRL secretion was significantly inhibited in 4 of 4
cultures (39–88% inhibition), as shown in Fig. 1, right panel.
In all prolactinoma (n 5 4; Fig. 2) and NFA or gonadotroph
cultures (n 5 4; Fig. 3) IFNa significantly inhibited hormone
secretion after 14 days of treatment. The percent inhibition
varied between 37–76% in prolactinoma cultures and be-
tween 27–62% in NFA and gonadotroph cultures after 14
days of treatment.
In the majority of the cultures the effects of IFNa and
octreotide or bromocriptine on hormone secretion were ad-
ditive. Figure 4 (GH-secreting pituitary adenoma cells) and
Fig. 5 (NFA cells) show the increasing, time-dependent, ad-
ditive effect of these drugs. Tables 1-3 show that significant
additive effects on hormone secretion were found in three of
five GH-secreting pituitary adenoma cultures, in two of two
prolactinoma cultures, and in one NFA culture in which the
combination of these drugs was studied. IFNa also signifi-
cantly inhibited intracellular GH concentrations in two of
four GH-secreting adenoma cultures (Table 1), whereas at
the same time treatment with octreotide or bromocriptine
induced a statistically significant accumulation of intracel-
lular GH concentrations (Table 1), suggesting a different
mechanism of action between IFNa, on the one hand, and
octreotide and bromocriptine, on the other hand. Both bro-
mocriptine and IFNa significantly inhibited intracellular
PRL concentrations in the GH-secreting pituitary adenoma
cultures (n 5 3; Table 1) and in the prolactinoma cultures (n 5
3; Table 2) and intracellular a-subunit and/or FSH concen-
trations in the NFA cultures (n 5 2; Table 3).
We also studied the effect of drug withdrawal on day 14
of treatment. In the majority of the cases we found that
withdrawal from IFNa treatment resulted in a recovery of
hormone secretion, suggesting that the inhibitory effect of
IFNa represents inhibition of hormone secretion and/or pro-
duction and not inhibition of cell proliferation or any cyto-
toxic effect. Representative examples of the effect of drug
withdrawal are shown in Fig. 4 (GH-secreting pituitary ad-
enoma), Fig. 5 (NFA), and Fig. 6 (prolactinoma). The absence
of any cytotoxic effect is further illustrated by the absence of
an effect of IFNa on the DNA content of the pituitary ade-
noma cells, which is shown in Fig. 7 for a GH-secreting
pituitary adenoma culture. No statistically significant inhi-
bition of IFNa on the DNA content of the cells was demon-
strated in six additional pituitary adenoma cultures (data not
shown).
Finally, the effect of IFNa on hormone secretion was dose
dependent, with IC50 values between 1.7–3.3 U/mL (mean,
2.3 6 0.3; Table 4). Data are shown in Fig. 7 (GH-secreting
pituitary adenoma), Table 2 (prolactinoma), and Table 3 (go-
nadotroph adenomas).
Gastroenteropancreatic tumors
For comparison we also evaluated the effect of IFNa on
insulin secretion by three insulinomas and on gastrin secre-
tion by a gastrinoma. In two of three insulinomas insulin
secretion was inhibited by 18% and 37% only at a high dose
of IFNa (50 U/mL), whereas in the gastrinoma a more sig-
nificant reduction of gastrin secretion was found (45% inhi-
bition by 50 U IFNa U/mL), as shown in Table 5.
FIG. 2. The effect of IFNa (50 U/mL) on PRL secretion by four cul-
tured human prolactinomas. Incubation time was 14 days in Trans-
well tissue culture inserts. Values are expressed as the percentage of
control hormone release and represent the mean 6 SE. *, P , 0.05 vs.
control. M, Control; f, IFNa.
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Discussion
In the majority of patients with GH-secreting pituitary
adenomas medical treatment with SS analogs and/or DA
agonists is, after transsphenoidal surgery, the therapy of
second choice (15). First choice medical therapy of this type
of pituitary adenomas is not frequently applied because SS
analogs and/or DA agonists induce only slight tumor
shrinkage in approximately 50% of the patients treated. This
is probably related to the fact that these drugs do not inhibit
hormonal synthesis in this type of pituitary adenomas (16,
17). In contrast, medical therapy with DA agonists is the first
choice therapy in patients with prolactinomas (23). The ma-
jority of patients with prolactinomas can be effectively
treated with DA agonists, resulting in lowered circulating
PRL levels and a reduction of tumor volume due to a potent
inhibition of hormonal synthesis by the drug (23). On the
other hand, some patients with prolactinomas cannot be
treated due to either resistance or adverse reactions to DA
agonists (14). Finally, at present no effective medical therapy
of patients with NFA is available (18). Taken together, these
data indicate that novel drugs that inhibit both hormonal
FIG. 3. The effect of IFNa (50–100 U/mL) on a-subunit and/or FSH secretion by cells from four cultured human NFA or gonadotroph adenomas.
Incubation time was 14 days in Transwell tissue culture inserts. Values are expressed as the percentage of control hormone release and represent
the mean 6 SE. *, P , 0.05 vs. control. ND, Not detectable. M, Control; f, IFNa.
FIG. 4. Additive inhibitory effect of octreotide (10 nmol/L) and IFNa (50 U/mL) on GH (left panel) and PRL (right panel) secretion by cultured
human GH-secreting pituitary adenoma cells (no. 12). The cells were incubated for 25 days without or with drugs in Transwell tissue culture
inserts. Values are the mean 6 SE and are expressed as the percentage of control hormone release at each time point. M, Octreotide (10 nmol/L);
F, IFNa (50 U/mL); f, octreotide plus IFNa.
FIG. 5. Additive inhibitory effect of bromocriptine (10 nmol/L) and
IFNa (50 U/mL) on a-subunit secretion by cultured human NFA cells
(no. 2). The cells were incubated for 21 days without or with drugs in
Transwell tissue culture inserts. Values are the mean 6 SE and are
expressed as the percentage of control hormone release at each time
point. M, Bromocriptine (10 nmol/L); F, IFNa (50 U/mL); f, bro-
mocriptine plus IFNa.
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hypersecretion and/or synthesis by pituitary adenomas
might be beneficial along with current medical therapy.
During the past 10 yr evidence has emerged that IFNs may
also play a regulatory role in pituitary hormone secretion
(2–8). IFNa-2a is a drug that has been used with variable
success in the treatment of several malignancies (1). In pa-
tients with neuroendocrine tumors such as carcinoids, treat-
ment with IFNa may control tumor growth, but also reduces
the secretion of tumor-related products in patient harboring
these tumors, thereby improving clinical symptomatology
(9–11). The decrease in the production of different peptide
hormones is caused by its blocking effect on intracellular
messenger ribonucleic acid formation (12).
In the present study we found that IFNa significantly
inhibits both hormone secretion and intracellular hormone
concentrations in primary cultures of human GH-secreting
pituitary adenomas, prolactinomas, and NFA or gonado-
troph adenomas. In the GH-secreting pituitary adenoma cul-
tures in which octreotide and/or bromocriptine significantly
inhibited hormone secretion, intracellular GH concentrations
were concomitantly increased, as has been reported previ-
ously (16). These data suggest that IFNa, on the one hand,
and octreotide and bromocriptine, on the other hand, act via
different mechanisms of action. Although octreotide and
bromocriptine act to inhibit hormone secretion via inhibition
of adenylyl cyclase activity and/or inhibition of calcium
fluxes (24), IFNa may inhibit hormone synthesis via inhibi-
tion of transcription of the GH gene, as has been proposed
for the effect of the drug on peptide production in neuroen-
docrine tumors (12). As we found that hormone secretion
recovered after withdrawal of treatment with IFNa in vitro,
and because the drug did not affect the DNA content of the
adenoma cell cultures, it is unlikely that IFNa inhibited cell
proliferation or induced cytotoxic effects. Moreover, we
found that even very low concentrations significantly inhib-
ited both hormone secretion and intracellular hormone con-
centrations in a dose-dependent manner.
In primary cultures of human prolactinomas, we found
that both bromocriptine and IFNa significantly inhibited
hormone secretion and intracellular hormone concentra-
tions. The observation that bromocriptine increased intra-
cellular GH concentrations in human GH-secreting pituitary
adenoma cultures, whereas the same drug significantly in-
hibited intracellular PRL concentrations in prolactinoma cul-
TABLE 1. The effect of long term treatment with IFNa and/or octreotide or bromocriptine on GH and PRL secretion and intracellular











8 Control 465 6 14 98 6 5
Octreotide (10 nmol/L) 283 6 8a 292 6 11a Not detectable Not detectable
Bromo (10 nmol/L) 429 6 24 184 6 8a
IFNa (50 U/mL) 323 6 17a 122 6 2a
9 Control 385 6 19 38 6 2 1337 6 63 267 6 36
Octreotide (10 nmol/L) 63 6 3a 424 6 21a 118 6 12a 90 6 15a
Bromo (10 nmol/L) 158 6 7a 317 6 8a 74 6 3a 99 6 17a
IFNa (100 U/mL) 253 6 15a 57 6 4a 536 6 54a 184 6 6a
10 Control 62 6 2
Octreotide (10 nmol/L) 51 6 2a Not determined Not detectable Not detectable
IFNa (50 U/mL) 58 6 1
Octreotide 1 IFNa 51 6 2a
11 Control 107 6 2 173 6 7
Octreotide (10 nmol/L) 73 6 1a 164 6 7
Bromo (10 nmol/L) 98 6 1a Not determined 13 6 2a Not determined
IFNa (100 U/mL) 68 6 2a 21 6 5a
Octreotide 1 IFNa 58 6 1a,b 29 6 5a,b
Bromo 1 IFNa 54 6 1a,b 9 6 1a
12 Control 602 6 22
Octreotide (10 nmol/L) 355 6 19a
Bromo (10 nmol/L) 572 6 26 Not determined Not detectable Not detectable
IFNa (50 U/mL) 500 6 24a
Octreotide 1 IFNa 228 6 13a,b
Bromo 1 IFNa 409 6 14a,b
13 Control 803 6 61 32 6 4 7187 6 229 1100 6 226
Bromo (10 nmol/L) 370 6 32a 58 6 3a 678 6 84a 575 6 51
IFNa (50 U/mL) 648 6 63a 19 6 3a 4387 6 282a 310 6 61a
Bromo 1 IFNa 337 6 32a 44 6 10 495 6 68a,b 468 6 117
14 Control 338 6 19 270 6 13 862 6 63 534 6 19
Octreotide (10 nmol/L) 194 6 22a 811 6 42a 308 6 5a 329 6 17a
IFNa (50 U/mL) 202 6 12a 172 6 10a 519 6 21a 331 6 21a
Octreotide 1 IFNa 85 6 4a,b 365 6 11a,b 163 6 5a,b 175 6 11a,b
Cells (105/well) were incubated for 14 days in Transwells without or with the drugs indicated. The medium was changed every 3–4 days.
Values represent hormone concentrations in the medium from days 12–14 of culture (3 days).
a P , 0.05 vs control.
b P , 0.05 vs. octreotide or bromocriptine (bromo) alone.
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tures suggests a different responsiveness of hormonal syn-
thesis to DA agonists between these two types of pituitary
adenomas. Of interest in this respect is that after long term
treatment in vitro both bromocriptine and IFNa significantly
inhibited intracellular PRL concentrations in the GH-secret-
ing pituitary adenomas despite a concomitant rise in intra-
cellular GH levels induced by bromocriptine. The inhibitory
effect of IFNa on intracellular PRL concentrations in pro-
lactinomas suggests that this drug might also induce tumor
shrinkage in patients with prolactinomas. Again of impor-
tance is our observation that very low concentrations in-
duced significant inhibition of intracellular PRL concentra-
tions. However, the four prolactinoma cultures that were
studied showed a high sensitivity to bromocriptine in vitro.
It remains to be established, therefore, whether DA agonist-
resistant prolactinomas respond in a comparable manner to
IFNa. Of special interest is a case report of a 45-yr old woman
suffering from antihepatitis C virus-positive chronic active
hepatitis and amenorrhea-galactorrhea syndrome due to a
PRL-secreting microadenoma, in whom IFNa treatment re-
sulted in normalization of plasma PRL levels and disappear-
ance of related symptoms (25).
FIG. 6. Recovery of PRL secretion by cultured human prolactinoma
cells (no. 2) after withdrawal of IFNa treatment (50 U/mL) on day 14
of treatment. Values are the mean 6 SE and are expressed as the
percentage of control hormone release at each time point.
TABLE 2. The effect of long term treatment with IFNa and/or
bromocriptine on PRL secretion and intracellular concentrations of
cultured human prolactinoma cells
Culture no. Treatment PRL secretion(ng/well 6 SE)
Intracellular PRL
(ng/well 6 SE)
1 Control 3199 6 34 102 6 13
Bromo (10 nmol/L) 115 6 15a 13 6 0a
IFNa (50 U/mL) 495 6 32a 14 6 0a
Bromo 1 IFNa 63 6 6a,b 6 6 0a,b
2 Control 5143 6 290
Bromo (10 nmol/L) 815 6 44a Not determined
IFNa (50 U/mL) 2897 6 151a
Bromo 1 IFNa 530 6 50a,b
3 Control 4730 6 135 109 6 9
IFNa (100 U/mL) 1190 6 32a 65 6 11a
IFNa (50 U/mL) 1757 6 103a 64 6 2a
IFNa (10 U/mL) 1873 6 123a 78 6 4a
IFNa (5 U/mL) 2557 6 67a 73 6 5a
IFNa (1 U/mL) 4400 6 48 101 6 5
4 Control 1940 6 75 379 6 14
Bromo (10 nmol/L) 375 6 26a 108 6 7a
IFNa (50 U/mL) 1218 6 70a 283 6 31a
Cells (105/well) were incubated for 14 days in Transwells without
or with the drugs indicated. The medium was changed every 3–4 days.
Values represent hormone concentrations in the medium from days
12–14 of culture (3 days).
a P , 0.05 vs. control.
b P , 0.05 vs. bromocriptine (bromo) alone.
TABLE 3. The effect of long term treatment with IFNa and/or bromocriptine on a-subunit and FSH secretion and intracellular
concentrations of cultured human clinically nonfunctioning (no. 1 and 2) or gonadotroph (no. 3 and 4) adenoma cells







1 Control 1.0 6 0.1 1.8 6 0.1 16.0 6 0.6 24.4 6 1.4
Bromo (10 nmol/L) 0.3 6 0.1a 1.0 6 0.1a 4.0 6 0.4a 11.5 6 0.6a
IFNa (100 U/mL) 0.4 6 0.0a 0.7 6 0.1a 8.6 6 0.2a 7.4 6 0.5a
2 Control 2.3 6 0.1 0.7 6 0.0 1.0 6 0.1
Bromo (10 nmol/L) 0.8 6 0.1a 0.3 6 0.1a 0.4 6 0.0a Not detectable
IFNa (100 U/mL) 0.9 6 0.1a 0.4 6 0.0a 0.6 6 0.1a
Bromo 1 IFNa 0.6 6 0.0a,b 0.3 6 0.0a 0.4 6 0.1a
3 Control 0.6 6 0.1 19.3 6 0.6
IFNa (50 U/mL) 0.4 6 0.0a 12.9 6 0.7a
IFNa (10 U/mL) 0.3 6 0.1a Not determined 12.7 6 0.7a Not determined
IFNa (5 U/mL) 0.4 6 0.0a 15.0 6 0.8a
IFNa (1 U/mL) 0.6 6 0.1 16.7 6 0.9a
4 Control 3.6 6 0.1
Bromo (10 nmol/L) 2.3 6 0.1a
IFNa (50 U/mL) Not detectable Not determined 2.6 6 0.1a Not determined
IFNa (10 U/mL) 2.8 6 0.1a
IFNa (1 U/mL) 3.2 6 0.1a
IFNa (0.1 U/mL) 3.4 6 0.1
Cells (105/well) were incubated for 14 days in Transwells without or with the drugs indicated. The medium was changed every 3–4 days.
Values represent hormone concentrations in the medium from days 12–14 of culture (3 days). LH was not detectable in the culture medium
or cell extracts.
a P , 0.05 vs. control.
b P , 0.05 vs. bromocriptine (bromo) alone.
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Finally, in line with the observations in prolactinoma cul-
tures, we found that both bromocriptine and IFNa signifi-
cantly inhibited both the secretion and intracellular hormone
concentrations of a-subunit and/or FSH in the NFA cultures.
The inhibitory effect of prolonged treatment with bromocrip-
tine on hormone production is in agreement with our pre-
vious observations (21). However, treatment with DA ago-
nists infrequently induces (minor) tumor shrinkage in
patients with NFA despite an inhibitory effect on circulating
gonadotropin and/or subunit levels (18). This may be related
to the low hormonal activity of this type of pituitary ade-
noma, and in this respect the effect of treatment with IFNa
on tumor volume is more uncertain than that in secreting
pituitary adenomas.
In the present study we showed that in the majority of the
cultures the inhibitory effects of IFNa were clearly additive to
the inhibitory effects of octreotide and bromocriptine. These
observations seem in line with studies in patients with carcinoid
tumors, which showed that the combination treatment with
octreotide and IFNa appears to be more effective, especially in
controlling clinical symptomatology rather than on tumor
mass, than treatment with either drug alone (26). Our obser-
vations suggest that IFNa treatment does not interfere in a
negative manner with the effects of the drugs currently used for
medical treatment of prolactinomas and GH-secreting pituitary
adenomas and can thus be used in combination. Moreover, in
patients with carcinoid tumors IFNa therapy was better toler-
ated when used in conjunction with SS analogs (26).
Recently, Katahira et al. (8), showed that both IFNa and
IFNg have a potent inhibitory effect on POMC gene expres-
sion in mouse AtT-20 pituitary tumor cells, thereby provid-
ing evidence for an inhibitory action of this group of proteins
at the level of transcription. If such an inhibition also occurs
in the human corticotropic tumor cell, ACTH production by
human corticotroph adenomas may be influenced by IFNa
as well. This may be very important, because at present no
medical treatment for this type of pituitary adenoma is
available.
Although the inhibitory effects of IFNa on hormone pro-
duction in secreting pituitary adenomas seems promising,
several points for the use of IFNa have to be stressed. Treat-
ment with IFNa is associated with considerable adverse re-
actions, including flu-like syndrome, fatigue, anorexia, and
depression (1). This is in sharp contrast with the use of SS
analogs and/or DA agonists, which have only mild adverse
reactions. On the other hand, we found in the present study
that a very low concentration IFNa (,5 U/mL) induced
significant inhibitory effects on both hormone secretion and
intracellular hormone concentrations. This concentration is
much lower than the concentrations reached in patients cur-
rently treated with IFNa for various malignancies or viral
infections (concentrations around 50–100 U/mL) (27–29).
Therefore, lower dose, long term IFNa treatment might be
considered. In this respect it is of interest that in treating other
malignancies lower dose treatment regimens have been sug-
gested to be more effective than high doses (30, 31). As a
result, lower dosages may be related to fewer adverse reac-
FIG. 7. Dose-dependent inhibition of GH secretion (upper panel) and
intracellular GH concentrations (middle panel) of cultured GH-se-
creting pituitary adenoma cells (no. 15) by IFNa. Cell number, as
measured by the DNA content of the cells, was not inhibited (lower
panel). Values are the mean 6 SE. *, P , 0.05 vs. control.
TABLE 4. Dose dependency of inhibition by IFNa-2a of hormone
secretion by cultured human pituitary adenoma cells
Type of adenoma Hormone(s) IC50(U/mL)
Maximal
inhibition (%)
GH-secreting (no. 15) GH 1.7 68
Prolactinoma (no. 3) PRL 3.3 70
Gonadotroph (no. 3) FSH/a-subunit 2.0/2.5 36/39
Gonadotroph (no. 4) FSH 2.0 32
IC50, Concentration of IFNa-2a inducing 50% of the maximal in-
hibition of hormone secretion. IC50 values were calculated from the
data presented in Fig. 7, Table 2, and Table 3.
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tions. This may be related to the fact that IFNa is part of a
physiologically active, complex biological system and should
thus not be considered as a conventional drug (30).
In conclusion, the potent inhibitory effect of IFNa on hor-
mone production by cultured pituitary adenomas suggests
that the drug might be a novel tool for medical treatment of
pituitary adenomas. On the other hand, considering the
above-indicated adverse reactions of IFNa treatment, the use
of this drug in the medical treatment of pituitary adenomas
should only be considered in inoperable, invasive aggres-
sive, DA agonist- and/or SS analog-resistant, secreting pi-
tuitary macroadenomas. Of additional interest is that IFNs
may have antiangiogenic activity as well (31).
References
1. Borden EC, Parkinson D. 1998 A perspective on the clinical effectiveness and
tolerance of interferon-a. Semin Oncol. 25:3–8.
2. Yamaguchi M, Koike K, Matsuzaki N, Yoshimoto Y, Taniguchi T, Miyake A,
Tanizawa O. 1991 The interferon family stimulates the secretions of prolactin and
interleukin-6 by the pituitary gland in vitro. J Endocrinol Invest. 14:457–461.
3. Vankelecom H, Carmeliet P, Heremans H, van Damme J, Dijkmans R,
Billiau A, Denef C. 1990 Interferon-g inhibits stimulated adrenocorticotropin,
prolactin and growth hormone secretion in normal rat anterior pituitary cell
cultures. Endocrinology. 126:2919–2926.
4. Gisslinger H, Svoboda T, Clodi M, Gilly B, Ludwig H, Havelec L, Luger A.
1993 Interferon-a stimulates the hypothalamic-pituitary-adrenal axis in vivo
and in vitro. Neuroendocrinology. 57:489–495.
5. Barbarino A, Colasanti S, Corsello SM, et al. 1995 Dexamethasone inhibition
of interferon-a2-induced stimulation of cortisol and growth hormone secretion
in chronic myeloproliferative syndrome. J Clin Endocrinol Metab. 80:
1329–1332.
6. Shimizu H, Ohtani K, Sato K, Nagamine T, Mori M. 1995 Increase in
serum interleukin-6, plasma ACTH and serum cortisol levels after systemic
interferon-a administration. Endocr J. 42:551–556.
7. Khan NU, Pulford KA, Farquharson MA, et al. 1989 The distribution of
immunoreactive interferon-alpha in normal human tissues. Immunology.
66:201–206.
8. Katahira M, Iwasaki Y, Aoki Y, Oiso Y, Saito H. 1998 Cytokine regulation of
the rat proopiomelanocortin gene expression in AtT-20 cells. Endocrinology.
139:2414–2422.
9. Arnold R. 1996 Medical treatment of metastasizing carcinoid tumors. World
J Surg. 20L:203–207.
10. Faiss S, Scherubl H, Riecken EO, Wiedenmann B. 1996 Drug therapy in
metastatic neuroendocrine tumors of the gastroenteropancreatic system. Re-
cent Results Cancer Res. 142:193–207.
11. Pisegna JR, Slimak GG, Doppman JL, et al. 1993 An evaluation of human
recombinant alpha interferon in patients with metastatic gastrinoma. Gastro-
enterology. 105:1179–1183.
12. Oberg K. 1992 The action of interferon a on human carcinoid tumours. Semin
Cancer Biol. 3:35–41.
13. Ransohoff RM. 1998 Cellular responses to interferons and other cytokines: the
JAK-STAT paradigm. N Engl J Med. 338:616–618.
14. Pellegrini I, Rasolonjanahary R, Gunz G, et al. 1989 Resistance to bromocrip-
tine in prolactinomas. J Clin Endocrinol Metab. 69:500–509.
15. Lamberts SWJ. 1988 The role of somatostatin in the regulation of anterior
pituitary hormone secretion and the use of its analogs in the treatment of
human pituitary tumors. Endocr Rev. 9:417–436.
16. Hofland LJ, Velkeniers B, van der Lely AJ, et al. 1992 Long-term in vitro
treatment of human growth hormone (GH)-secreting pituitary adenoma cells
with octreotide causes accumulation of intracellular GH and GH mRNA levels.
Clin Endocrinol (Oxf). 37:240–248.
17. Davis JRE, Wilson EM, Vidal ME, Johnson AP, Lynch SS, Sheppard MC.
1989 Regulation of growth hormone secretion and messenger ribonucleic acid
accumulation in human somatotropinoma cells in vitro. J Clin Endocrinol
Metab. 69:704–708.
18. Katznelson L, Alexander JM, Klibanski A. 1993 Clinically nonfunctioning
pituitary adenomas. J Clin Endocrinol Metab. 76:1089–1094.
19. Hofland LJ, van Koetsveld PM, Verleun TM, Lamberts SWJ. 1989 Glyco-
protein hormone a-subunit and prolactin release by cultured pituitary ade-
noma cells from acromegalic patients: correlation with GH release. Clin En-
docrinol (Oxf). 30:601–611.
20. Lamberts SWJ, Hofland LJ, van Koetsveld PM, et al. 1990 Parallel in vivo and
in vitro detection of functional somatostatin receptors in human endocrine
pancreatic tumors: consequences with regard to diagnosis, localization, and
therapy. J Clin Endocrinol Metab. 71:566–574.
21. Kwekkeboom DJ, Hofland LJ, van Koetsveld PM, Singh R, van den Berge
JH, Lamberts SWJ. 1990 Bromocriptine increasingly suppresses the in vitro
gonadotropin and a-subunit release from pituitary adenomas during long-
term culture. J Clin Endocrinol Metab. 71:718–724.
22. Hofland LJ, van Koetsveld PM, Lamberts SWJ. 1990 Percoll density gradient
centrifugation of rat pituitary tumor cells: a study of functional heterogeneity
within and between tumors with respect to growth rates, prolactin production and
responsiveness to the somatostatin analog SMS 201–995. Eur J Cancer. 26:37–44.
23. Bevan JS, Webster J, Burke CW, Scanlon MF. 1992 Dopamine agonists and
pituitary tumor shrinkage. Endocr Rev. 13:220–240.
24. Schonbrunn A. 1990 Somatostatin action in pituitary cells involves two in-
dependent transduction pathways. Metabolism. 39:96–100.
25. Zennaro R, Petracca EG, Paolini R, Ramazzina E. 1996 Normalization of the
prolactin values during alfa-interferon therapy: the considerations with a
female patient with anti-HCV-positive chronic hepatitis and prolactin-secret-
ing hypophyseal microadenoma. Clin Ther 147:169–171.
26. O¨berg K. 1996 Interferon-a versus somatostatin or the combination of both in
gastro-enteropancreatic tumours. Digestion. 57:81–83.
27. Shah I, Band J, Samson M, et al. 1984 Pharmacokinetics and tolerance of
intravenous and intramuscular recombinant a2 interferon in patients with
malignancies. Am J Hematol. 17:363–371.
28. Wells RJ, Weck PK, Baehner RL, et al. 1988 Interferon-an1 in children with
recurrent acute lymphocytic leukemia: a phase I study of pharmacokinetics
and tolerance. J Interferon Res. 8:309–318.
29. Radwanski E, Perentesis G, Jacobs SJ, Oden E, Affrime M, Symchowicz S,
Zampaglione N. 1987 Pharmacokinetics of interferon-a-2b in healthy volun-
teers. J Clin Pharmacol. 27:432–435.
30. Dianzani F. 1992 Interferon treatments: how to use an endogenous system as
a therapeutic agent. J Interferon Res. 12:109–118.
31. Dinney CPN, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, Fidler
IJ. 1998 Inhibition of basic fibroblast growth factor expression, angiogenesis,
and growth of human bladder carcinoma in mice by systemic interferon-a
administration. Cancer Res. 58:808–814.
TABLE 5. Effect of long term in vitro treatment with IFNa-2a on insulin or gastrin secretion by cultured insulinoma and gastrinoma
cells
Culture no. Treatment Insulin or gastrin secretion(mU/L z well 6 SE) % of control
Insulinoma no. 1 Control 127 6 5 100
IFNa (10 U/mL) 123 6 21 97
IFNa (50 U/mL) 134 6 12 106
Insulinoma no. 2 Control 14,749 6 409 100
IFNa (10 U/mL) 12,083 6 329 82
IFNa (50 U/mL) 9,247 6 631a 63
Insulinoma no. 3 Control 3,304 6 102 100
IFNa (50 U/mL) 2,721 6 55a 82
Gastrinoma Control 26,930 6 2,893 100
IFNa (50 U/mL) 14,840 6 2,281a 55
Cells (105/well) were incubated for 14 days in Transwells without or with IFNa-2a. The medium was changed every 3–4 days. Values represent
hormone concentrations in the medium from days 12–14 of culture (3 days).
a P , 0.05 vs. control cells.
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